Difference between revisions of "HAEM5:Volunteer Assignments and Opportunities"
Jump to navigation
Jump to search
[unchecked revision] | [unchecked revision] |
Line 62: | Line 62: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease|| || || || || ||FQR|| || | + | |[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease||PENDING|| || || || ||FQR|| || |
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive | |Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive | ||
|Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | |Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | ||
Line 69: | Line 69: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Chronic neutrophilic leukaemia|Chronic neutrophilic leukaemia]]||Disease|| | + | |[[HAEM5:Chronic neutrophilic leukaemia|Chronic neutrophilic leukaemia]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Chronic Neutrophilic Leukemia (CNL) | |Chronic Neutrophilic Leukemia (CNL) | ||
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine <nowiki>**</nowiki>contributed equally | |Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine <nowiki>**</nowiki>contributed equally | ||
Line 76: | Line 77: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease|| | + | |[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Chronic Eosinophilic Leukemia, Not Otherwise Specified | |Chronic Eosinophilic Leukemia, Not Otherwise Specified | ||
|Chelsea D. Kramish; Daynna J.Wolff | |Chelsea D. Kramish; Daynna J.Wolff | ||
Line 83: | Line 85: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease|| | + | |[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Polycythemia Vera (PV) | |Polycythemia Vera (PV) | ||
|Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center | |Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center | ||
Line 90: | Line 93: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease|| | + | |[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Essential Thrombocythemia (ET) | |Essential Thrombocythemia (ET) | ||
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN | |Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN | ||
Line 97: | Line 101: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Primary myelofibrosis|Primary myelofibrosis]]||Disease|| | + | |[[HAEM5:Primary myelofibrosis|Primary myelofibrosis]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Primary Myelofibrosis (PMF) | |Primary Myelofibrosis (PMF) | ||
|T. Niroshi Senaratne, UCLA | |T. Niroshi Senaratne, UCLA | ||
Line 104: | Line 109: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Juvenile myelomonocytic leukaemia|Juvenile myelomonocytic leukaemia]]||Disease|| '''Sarah Rapisardo, PhD, FACMG''' | | + | |[[HAEM5:Juvenile myelomonocytic leukaemia|Juvenile myelomonocytic leukaemia]]||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |PENDING |
+ | | || || || ||FQR|| || | ||
|Juvenile Myelomonocytic Leukemia (JMML) | |Juvenile Myelomonocytic Leukemia (JMML) | ||
|<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki> | |<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki> | ||
Line 115: | Line 121: | ||
|FQR has emailed SR several times, last 4/20/22 | |FQR has emailed SR several times, last 4/20/22 | ||
|- | |- | ||
− | |[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease|| | + | |[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Myeloproliferative Neoplasm (MPN), Unclassifiable | |Myeloproliferative Neoplasm (MPN), Unclassifiable | ||
|Thomas Lee, MD, PhD, University of California, Los Angeles | |Thomas Lee, MD, PhD, University of California, Los Angeles | ||
Line 122: | Line 129: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Cutaneous mastocytosis|Cutaneous mastocytosis]]||Disease|| | + | |[[HAEM5:Cutaneous mastocytosis|Cutaneous mastocytosis]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Cutaneous Mastocytosis | |Cutaneous Mastocytosis | ||
|S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD | |S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD | ||
Line 129: | Line 137: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Systemic mastocytosis|Systemic mastocytosis]]||Disease|| || || || || ||FQR|| || | + | |[[HAEM5:Systemic mastocytosis|Systemic mastocytosis]]||Disease||PENDING|| || || || ||FQR|| || |
|Systemic Mastocytosis | |Systemic Mastocytosis | ||
|'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University | |'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University | ||
Line 136: | Line 144: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Mast cell sarcoma|Mast cell sarcoma]]||Disease|| | + | |[[HAEM5:Mast cell sarcoma|Mast cell sarcoma]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Mast Cell Sarcoma | |Mast Cell Sarcoma | ||
|Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL | |Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL | ||
Line 143: | Line 152: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Myelodysplastic neoplasm with low blasts and 5q deletion|Myelodysplastic neoplasm with low blasts and 5q deletion]]||Disease|| | + | |[[HAEM5:Myelodysplastic neoplasm with low blasts and 5q deletion|Myelodysplastic neoplasm with low blasts and 5q deletion]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Myelodysplastic Syndrome (MDS) with Isolated del(5q) | |Myelodysplastic Syndrome (MDS) with Isolated del(5q) | ||
|Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG | |Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG | ||
Line 150: | Line 160: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease|| | + | |[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 178: | Line 189: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |[[HAEM5:Myelodysplastic neoplasm with increased blasts|Myelodysplastic neoplasm with increased blasts]]||Disease|| | + | |[[HAEM5:Myelodysplastic neoplasm with increased blasts|Myelodysplastic neoplasm with increased blasts]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Myelodysplastic Syndrome (MDS) with Excess Blasts | |Myelodysplastic Syndrome (MDS) with Excess Blasts | ||
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | |Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | ||
Line 185: | Line 197: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease|| | + | |[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Refractory Cytopenia of Childhood | |Refractory Cytopenia of Childhood | ||
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | |Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | ||
Line 192: | Line 205: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Childhood myelodysplastic neoplasm with increased blasts|Childhood myelodysplastic neoplasm with increased blasts]]||Disease|| | + | |[[HAEM5:Childhood myelodysplastic neoplasm with increased blasts|Childhood myelodysplastic neoplasm with increased blasts]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Refractory Cytopenia of Childhood | |Refractory Cytopenia of Childhood | ||
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | |Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | ||
Line 199: | Line 213: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Chronic myelomonocytic leukaemia|Chronic myelomonocytic leukaemia]]||Disease|| | + | |[[HAEM5:Chronic myelomonocytic leukaemia|Chronic myelomonocytic leukaemia]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Chronic Myelomonocytic Leukemia (CMML) | |Chronic Myelomonocytic Leukemia (CMML) | ||
|Linsheng Zhang, MD, PhD | |Linsheng Zhang, MD, PhD | ||
Line 206: | Line 221: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia|Myelodysplastic/myeloproliferative neoplasm with neutrophilia]]||Disease|| | + | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia|Myelodysplastic/myeloproliferative neoplasm with neutrophilia]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative | |Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative | ||
|Linsheng Zhang, MD, PhD | |Linsheng Zhang, MD, PhD | ||
Line 213: | Line 229: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis]]||Disease|| | + | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) | |Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) | ||
|Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine | |Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine | ||
Line 220: | Line 237: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease|| | + | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable | |Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable | ||
|Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia | |Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia | ||
Line 229: | Line 247: | ||
|[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]] | |[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 245: | Line 263: | ||
|[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]] | |[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 261: | Line 279: | ||
|[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]] | |[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 277: | Line 295: | ||
|[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]] | |[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 293: | Line 311: | ||
|[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]] | |[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 309: | Line 327: | ||
|[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]] | |[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 325: | Line 343: | ||
|[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]] | |[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 341: | Line 359: | ||
|[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]] | |[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 373: | Line 391: | ||
|[[HAEM5:Acute myeloid leukaemia with NPM1 mutation|Acute myeloid leukaemia with NPM1 mutation]] | |[[HAEM5:Acute myeloid leukaemia with NPM1 mutation|Acute myeloid leukaemia with NPM1 mutation]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 389: | Line 407: | ||
|[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]] | |[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 405: | Line 423: | ||
|[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]] | |[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 437: | Line 455: | ||
|[[HAEM5:Acute myeloid leukaemia with minimal differentiation|Acute myeloid leukaemia with minimal differentiation]] | |[[HAEM5:Acute myeloid leukaemia with minimal differentiation|Acute myeloid leukaemia with minimal differentiation]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 453: | Line 471: | ||
|[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]] | |[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 469: | Line 487: | ||
|[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]] | |[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 485: | Line 503: | ||
|[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]] | |[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 501: | Line 519: | ||
|[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]] | |[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 517: | Line 535: | ||
|[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]] | |[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 533: | Line 551: | ||
|[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]] | |[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 549: | Line 567: | ||
|[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]] | |[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 565: | Line 583: | ||
|[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]] | |[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 600: | Line 618: | ||
|[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]] | |[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 616: | Line 634: | ||
|[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]] | |[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 632: | Line 650: | ||
|[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]] | |[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 648: | Line 666: | ||
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRA rearrangement|Myeloid/lymphoid neoplasm with PDGFRA rearrangement]] | |[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRA rearrangement|Myeloid/lymphoid neoplasm with PDGFRA rearrangement]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 664: | Line 682: | ||
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRB rearrangement|Myeloid/lymphoid neoplasm with PDGFRB rearrangement]] | |[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRB rearrangement|Myeloid/lymphoid neoplasm with PDGFRB rearrangement]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 680: | Line 698: | ||
|[[HAEM5:Myeloid/lymphoid neoplasm with FGFR1 rearrangement|Myeloid/lymphoid neoplasm with FGFR1 rearrangement]] | |[[HAEM5:Myeloid/lymphoid neoplasm with FGFR1 rearrangement|Myeloid/lymphoid neoplasm with FGFR1 rearrangement]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 763: | Line 781: | ||
|[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]] | |[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 779: | Line 797: | ||
|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]] | |[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 811: | Line 829: | ||
|[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]] | |[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 827: | Line 845: | ||
|[[HAEM5:Mixed-phenotype acute leukaemia, T/myeloid|Mixed-phenotype acute leukaemia, T/myeloid]] | |[[HAEM5:Mixed-phenotype acute leukaemia, T/myeloid|Mixed-phenotype acute leukaemia, T/myeloid]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 843: | Line 861: | ||
|[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]] | |[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 875: | Line 893: | ||
|[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]] | |[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 937: | Line 955: | ||
|[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]] | |[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 953: | Line 971: | ||
|[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]] | |[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 969: | Line 987: | ||
|[[HAEM5:Langerhans cell sarcoma|Langerhans cell sarcoma]] | |[[HAEM5:Langerhans cell sarcoma|Langerhans cell sarcoma]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,081: | Line 1,099: | ||
|[[HAEM5:Histiocytic sarcoma|Histiocytic sarcoma]] | |[[HAEM5:Histiocytic sarcoma|Histiocytic sarcoma]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,191: | Line 1,209: | ||
|[[HAEM5:KSHV/HHV8-associated multicentric Castleman disease|KSHV/HHV8-associated multicentric Castleman disease]] | |[[HAEM5:KSHV/HHV8-associated multicentric Castleman disease|KSHV/HHV8-associated multicentric Castleman disease]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,207: | Line 1,225: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,223: | Line 1,241: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,239: | Line 1,257: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,255: | Line 1,273: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]] | ||
|Disease | |Disease | ||
− | |Holli authoring - Complete? Looks like needs more editing of tables | + | |Holli Drendel authoring - Complete? Looks like needs more editing of tables |
| | | | ||
| | | | ||
Line 1,271: | Line 1,289: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,287: | Line 1,305: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,303: | Line 1,321: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,319: | Line 1,337: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,351: | Line 1,369: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,367: | Line 1,385: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,448: | Line 1,466: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease|| | + | |[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING |
+ | | || || || ||Shivani Golem (SG) | ||
| || | | || | ||
|Monoclonal B-cell Lymphocytosis | |Monoclonal B-cell Lymphocytosis | ||
Line 1,468: | Line 1,487: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease|| | + | |[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease||PENDING |
+ | | || || || ||SG|| || | ||
|Hairy Cell Leukemia | |Hairy Cell Leukemia | ||
|Snehal Patel, MD, PhD | |Snehal Patel, MD, PhD | ||
Line 1,475: | Line 1,495: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease|| | + | |[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease||PENDING |
+ | | || || || ||SG|| || | ||
|Splenic Marginal Zone Lymphoma | |Splenic Marginal Zone Lymphoma | ||
|Snehal Patel, MD, PhD | |Snehal Patel, MD, PhD | ||
Line 1,482: | Line 1,503: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease|| | + | |[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease||PENDING |
+ | | || || || ||SG|| || | ||
|Splenic Diffuse Red Pulp Small B-cell Lymphoma | |Splenic Diffuse Red Pulp Small B-cell Lymphoma | ||
|Snehal Patel, MD, PhD | |Snehal Patel, MD, PhD | ||
Line 1,491: | Line 1,513: | ||
|[[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|Splenic B-cell lymphoma/leukaemia with prominent nucleoli]] | |[[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|Splenic B-cell lymphoma/leukaemia with prominent nucleoli]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,507: | Line 1,529: | ||
|[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]] | |[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,523: | Line 1,545: | ||
|[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]] | |[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,557: | Line 1,579: | ||
|[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]] | |[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,573: | Line 1,595: | ||
|[[HAEM5:Paediatric nodal marginal zone lymphoma|Paediatric nodal marginal zone lymphoma]] | |[[HAEM5:Paediatric nodal marginal zone lymphoma|Paediatric nodal marginal zone lymphoma]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,621: | Line 1,643: | ||
|[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]] | |[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,653: | Line 1,675: | ||
|[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]] | |[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,669: | Line 1,691: | ||
|[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]] | |[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,685: | Line 1,707: | ||
|[[HAEM5:Mantle cell lymphoma|Mantle cell lymphoma]] | |[[HAEM5:Mantle cell lymphoma|Mantle cell lymphoma]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,731: | Line 1,753: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease|| | + | |[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease||PENDING |
+ | | || || || ||GC|| || | ||
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified | |Diffuse Large B-cell Lymphoma, Not Otherwise Specified | ||
|Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center | |Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center | ||
Line 1,745: | Line 1,768: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease|| | + | |[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease||PENDING |
+ | | || || || ||GC|| || | ||
|High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | |High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | ||
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland | |Kate Berry, MBBS, BBus (Hons), Pathology Queensland | ||
Line 1,752: | Line 1,776: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease|| | + | |[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease||PENDING |
+ | | || || || ||GC|| || | ||
|ALK-Positive Large B-cell Lymphoma | |ALK-Positive Large B-cell Lymphoma | ||
|Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) | |Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) | ||
Line 1,759: | Line 1,784: | ||
|Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23 | |Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23 | ||
|- | |- | ||
− | |[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease|| | + | |[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease||PENDING |
+ | | || || || ||GC|| || | ||
|Large B-cell Lymphoma with IRF4 Rearrangement | |Large B-cell Lymphoma with IRF4 Rearrangement | ||
|Afia Hasnain, MBBS, PhD | |Afia Hasnain, MBBS, PhD | ||
Line 1,766: | Line 1,792: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease|| | + | |[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease||PENDING |
+ | | || || || ||GC|| || | ||
|Burkitt-Like Lymphoma with 11q Aberration | |Burkitt-Like Lymphoma with 11q Aberration | ||
|Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | |Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | ||
Line 1,794: | Line 1,821: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease|| | + | |[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease||PENDING |
+ | | || || || ||GC|| ||Note: previously a subset DLBCL assoc with chronic inflam | ||
|Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior) | |Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 1,808: | Line 1,836: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease|| | + | |[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease||PENDING |
+ | | || || || ||GC|| || | ||
|Plasmablastic Lymphoma | |Plasmablastic Lymphoma | ||
|Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | |Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | ||
Line 1,815: | Line 1,844: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease|| | + | |[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease||PENDING |
+ | | || || || ||GC|| || | ||
|(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS | |(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS | ||
|(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital | |(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital | ||
Line 1,829: | Line 1,859: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease|| | + | |[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease||PENDING |
+ | | || || || ||GC|| || | ||
|Intravascular Large B-cell Lymphoma | |Intravascular Large B-cell Lymphoma | ||
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy | |Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy | ||
Line 1,850: | Line 1,881: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease|| | + | |[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease||PENDING |
+ | | || || || ||GC|| || | ||
|High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS) | |High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS) | ||
|Aiko Otsubo, PhD, Indiana University, Holli Drendel | |Aiko Otsubo, PhD, Indiana University, Holli Drendel | ||
Line 1,857: | Line 1,889: | ||
| | | | ||
|- | |- | ||
− | |Burkitt lymphoma||Disease|| | + | |Burkitt lymphoma||Disease||PENDING |
+ | | || || || ||GC|| || | ||
|Burkitt Lymphoma | |Burkitt Lymphoma | ||
|Becky Leung, MBBS (Hons), BSc, Pathology Queensland | |Becky Leung, MBBS (Hons), BSc, Pathology Queensland | ||
Line 1,922: | Line 1,955: | ||
| | | | ||
|- | |- | ||
− | |Classic Hodgkin lymphoma||Disease|| | + | |Classic Hodgkin lymphoma||Disease||PENDING |
+ | | || || ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma | ||
|GC|| || | |GC|| || | ||
|(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma | |(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma | ||
Line 1,975: | Line 2,009: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Immunoglobulin-related (AL) amyloidosis||Disease|| | + | |Immunoglobulin-related (AL) amyloidosis||Disease||PENDING |
+ | | || || || ||SG | ||
| || | | || | ||
|Primary Amyloidosis | |Primary Amyloidosis | ||
Line 1,983: | Line 2,018: | ||
| | | | ||
|- | |- | ||
− | |Monoclonal immunoglobulin deposition disease||Disease|| | + | |Monoclonal immunoglobulin deposition disease||Disease||PENDING |
+ | | || || || ||SG | ||
| || | | || | ||
|Light Chain and Heavy Chain Deposition Disease | |Light Chain and Heavy Chain Deposition Disease | ||
Line 1,999: | Line 2,035: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Gamma heavy chain disease||Disease|| | + | |Gamma heavy chain disease||Disease||PENDING |
+ | | || || || ||SG | ||
| || | | || | ||
|Gamma Heavy Chain Disease | |Gamma Heavy Chain Disease | ||
Line 2,015: | Line 2,052: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Plasmacytoma||Disease|| | + | |Plasmacytoma||Disease||PENDING |
+ | | || || ||author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga) | ||
|SG | |SG | ||
| || | | || | ||
Line 2,024: | Line 2,062: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Plasma cell myeloma / multiple myeloma||Disease|| | + | |Plasma cell myeloma / multiple myeloma||Disease||PENDING |
+ | | || || ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page||SG | ||
| || | | || | ||
|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants | |(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants | ||
Line 2,032: | Line 2,071: | ||
| | | | ||
|- | |- | ||
− | |Plasma cell neoplasms with associated paraneoplastic syndrome||Disease|| | + | |Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||PENDING |
+ | | || || ||Note: author needs to include POEMS, TEMPI, and look for AESOP content | ||
|SG | |SG | ||
| || | | || | ||
Line 2,102: | Line 2,142: | ||
|Early T-precursor lymphoblastic leukaemia / lymphoma | |Early T-precursor lymphoblastic leukaemia / lymphoma | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 2,132: | Line 2,172: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |T-large granular lymphocytic leukaemia||Disease|| | + | |T-large granular lymphocytic leukaemia||Disease||PENDING |
+ | | || || || ||SK|| || | ||
|T-cell Large Granular Lymphocytic Leukemia | |T-cell Large Granular Lymphocytic Leukemia | ||
|Michelle Don, MD, MS | |Michelle Don, MD, MS | ||
Line 2,139: | Line 2,180: | ||
| | | | ||
|- | |- | ||
− | |NK-large granular lymphocytic leukaemia||Disease|| | + | |NK-large granular lymphocytic leukaemia||Disease||PENDING |
+ | | || || || ||SK|| || | ||
|Chronic Lymphoproliferative Disorder of NK Cells | |Chronic Lymphoproliferative Disorder of NK Cells | ||
|Michelle Don, MD | |Michelle Don, MD | ||
Line 2,146: | Line 2,188: | ||
| | | | ||
|- | |- | ||
− | |Adult T-cell leukaemia/lymphoma||Disease|| | + | |Adult T-cell leukaemia/lymphoma||Disease||PENDING |
+ | | || || || ||SK|| || | ||
|Adult T-cell Leukemia/Lymphoma | |Adult T-cell Leukemia/Lymphoma | ||
|Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center | |Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center | ||
Line 2,153: | Line 2,196: | ||
| | | | ||
|- | |- | ||
− | |Sezary syndrome||Disease|| | + | |Sezary syndrome||Disease||PENDING |
+ | | || || || ||SK|| || | ||
|Sézary Syndrome | |Sézary Syndrome | ||
|Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina | |Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina | ||
Line 2,160: | Line 2,204: | ||
| | | | ||
|- | |- | ||
− | |Aggressive NK-cell leukaemia||Disease|| | + | |Aggressive NK-cell leukaemia||Disease||PENDING |
+ | | || || || ||SK|| || | ||
|Aggressive NK-cell Leukemia | |Aggressive NK-cell Leukemia | ||
|Shanelle De Lancy, MD, Shashirekha Shetty, PhD | |Shanelle De Lancy, MD, Shashirekha Shetty, PhD | ||
Line 2,181: | Line 2,226: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Mycosis fungoides||Disease|| | + | |Mycosis fungoides||Disease||PENDING |
+ | | || || || ||SK|| || | ||
|Mycosis Fungoides | |Mycosis Fungoides | ||
|Jane Scribner, MD and Daynna J. Wolff, PhD | |Jane Scribner, MD and Daynna J. Wolff, PhD | ||
Line 2,195: | Line 2,241: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease|| | + | |Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||PENDING |
+ | | || || || ||SK|| || | ||
|Primary Cutaneous Anaplastic Large Cell Lymphoma | |Primary Cutaneous Anaplastic Large Cell Lymphoma | ||
|Theresa Spivey, MD, Shashirekha Shetty, PhD | |Theresa Spivey, MD, Shashirekha Shetty, PhD | ||
Line 2,230: | Line 2,277: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Indolent T-cell lymphoma of the gastrointestinal tract||Disease|| | + | |Indolent T-cell lymphoma of the gastrointestinal tract||Disease||PENDING |
+ | | || || || ||SK|| || | ||
|Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract | |Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract | ||
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | |Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | ||
Line 2,244: | Line 2,292: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Enteropathy-associated T-cell lymphoma||Disease|| | + | |Enteropathy-associated T-cell lymphoma||Disease||PENDING |
+ | | || || || ||SK|| || | ||
|Enteropathy-Associated T-cell Lymphoma | |Enteropathy-Associated T-cell Lymphoma | ||
|*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD | |*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD | ||
Line 2,251: | Line 2,300: | ||
| | | | ||
|- | |- | ||
− | |Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease|| | + | |Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||PENDING |
+ | | || || || ||SK|| || | ||
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma | |Monomorphic Epitheliotropic Intestinal T-cell Lymphoma | ||
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | |Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | ||
Line 2,258: | Line 2,308: | ||
| | | | ||
|- | |- | ||
− | |Intestinal T-cell lymphoma, NOS||Disease|| | + | |Intestinal T-cell lymphoma, NOS||Disease||PENDING |
+ | | || || || ||SK|| || | ||
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS) | |Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS) | ||
|Derick Okwan MD, PhD (Stanford Medicine, CA) Sumire Kitahara MD (Cedars-Sinai, CA) | |Derick Okwan MD, PhD (Stanford Medicine, CA) Sumire Kitahara MD (Cedars-Sinai, CA) | ||
Line 2,265: | Line 2,316: | ||
| | | | ||
|- | |- | ||
− | |Hepatosplenic T-cell lymphoma||Disease|| | + | |Hepatosplenic T-cell lymphoma||Disease||PENDING |
+ | | || || || ||SK|| || | ||
|Hepatosplenic T-cell Lymphoma | |Hepatosplenic T-cell Lymphoma | ||
|Michelle Don, MD, MS | |Michelle Don, MD, MS | ||
Line 2,272: | Line 2,324: | ||
| | | | ||
|- | |- | ||
− | |ALK-positive anaplastic large cell lymphoma||Disease|| | + | |ALK-positive anaplastic large cell lymphoma||Disease||PENDING |
+ | | || || || ||SK|| || | ||
|Anaplastic Large Cell Lymphoma, ALK-Positive | |Anaplastic Large Cell Lymphoma, ALK-Positive | ||
|Miguel Gonzalez Mancera, MD | |Miguel Gonzalez Mancera, MD | ||
Line 2,283: | Line 2,336: | ||
| | | | ||
|- | |- | ||
− | |ALK-negative anaplastic large cell lymphoma||Disease|| | + | |ALK-negative anaplastic large cell lymphoma||Disease||PENDING |
+ | | || || || ||SK|| || | ||
|Anaplastic Large Cell Lymphoma, ALK-Negative | |Anaplastic Large Cell Lymphoma, ALK-Negative | ||
|Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA | |Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA | ||
Line 2,290: | Line 2,344: | ||
| | | | ||
|- | |- | ||
− | |Breast implant-associated anaplastic large cell lymphoma||Disease|| | + | |Breast implant-associated anaplastic large cell lymphoma||Disease||PENDING |
+ | | || || || ||SK|| || | ||
|Breast Implant-Associated Anaplastic Large Cell Lymphoma | |Breast Implant-Associated Anaplastic Large Cell Lymphoma | ||
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center | |Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center | ||
Line 2,313: | Line 2,368: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Nodal TFH cell lymphoma, NOS||Disease|| | + | |Nodal TFH cell lymphoma, NOS||Disease||PENDING |
+ | | || || || ||SK|| || | ||
|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype | |Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype | ||
|Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD | |Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD | ||
Line 2,362: | Line 2,418: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Systemic EBV-positive T-cell lymphoma of childhood||Disease|| | + | |Systemic EBV-positive T-cell lymphoma of childhood||Disease||PENDING |
+ | | || || || ||SK|| || | ||
|Systemic EBV-Positive T-cell Lymphoma of Childhood | |Systemic EBV-Positive T-cell Lymphoma of Childhood | ||
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA | |Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA | ||
Line 2,401: | Line 2,458: | ||
|Follicular dendritic cell sarcoma | |Follicular dendritic cell sarcoma | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | |
Revision as of 23:54, 23 December 2023
Welcome!
- For assignments, please see the "Author" column below (3rd column from left).
- If empty (no name is present), please volunteer to create content for that disease!
- If "PENDING" is present, the original author of that disease page is currently being contacted about revising the content.
- To volunteer, please [Contact us] with your page of interest.
- Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content added.
Disease (5th Edition) | Page Type | Author (5th Edition) (Note: please indicate trainees in parentheses) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Content Status (5th Edition)(Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review (5th Edition) | Notes (5th Edition) | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) | Prior Content Status (4th Edition)(Pending or Complete) | Prior Date of Last Editor Review (4th Edition) | Prior Notes (4th Edition) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clonal haematopoiesis | Disease | Fabiola Quintero-Rivera (FQR) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Clonal cytopenias of undetermined significance | Disease | FQR | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Chronic myeloid leukaemia | Disease | PENDING | FQR | Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive | Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | Complete | Date page was created | |||||||
Chronic neutrophilic leukaemia | Disease | PENDING | FQR | Chronic Neutrophilic Leukemia (CNL) | Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine **contributed equally | Complete | Date page was created | |||||||
Chronic eosinophilic leukaemia | Disease | PENDING | FQR | Chronic Eosinophilic Leukemia, Not Otherwise Specified | Chelsea D. Kramish; Daynna J.Wolff | complete/pending faculty review | ||||||||
Polycythaemia vera | Disease | PENDING | FQR | Polycythemia Vera (PV) | Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center | Complete | ||||||||
Essential thrombocythaemia | Disease | PENDING | FQR | Essential Thrombocythemia (ET) | Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN | Complete | ||||||||
Primary myelofibrosis | Disease | PENDING | FQR | Primary Myelofibrosis (PMF) | T. Niroshi Senaratne, UCLA | Complete | 8/4/2020 before submission |
|||||||
Juvenile myelomonocytic leukaemia | Disease | PENDING | FQR | Juvenile Myelomonocytic Leukemia (JMML) | Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology
Associate Director | Division of Molecular Pathology, Genetics and Genomics Duke University Health System Clinical Laboratories |
PENDING importing content and reference formatting | FQR has emailed SR several times, last 4/20/22 | |||||||
Myeloproliferative neoplasm, NOS | Disease | PENDING | FQR | Myeloproliferative Neoplasm (MPN), Unclassifiable | Thomas Lee, MD, PhD, University of California, Los Angeles | Complete | ||||||||
Cutaneous mastocytosis | Disease | PENDING | FQR | Cutaneous Mastocytosis | S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD | Complete | ||||||||
Systemic mastocytosis | Disease | PENDING | FQR | Systemic Mastocytosis | Abdullah Osme, MD, University Hospitals Cleveland Medical Center, Case Western Reserve University Shashi Shetty, Ph.D. FACMG, FCCMG, University Hospitals Cleveland Medical Center, Case Western Reserve University | Complete | ||||||||
Mast cell sarcoma | Disease | PENDING | FQR | Mast Cell Sarcoma | Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL | Complete | ||||||||
Myelodysplastic neoplasm with low blasts and 5q deletion | Disease | PENDING | FQR | Myelodysplastic Syndrome (MDS) with Isolated del(5q) | Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG | Complete | ||||||||
Myelodysplastic neoplasm with low blasts and SF3B1 mutation | Disease | PENDING | FQR | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||||
Myelodysplastic neoplasm with biallelic TP53 inactivation | Disease | Eric McGinnis (assigned to new 5th edition page - FQR is this reviewed?) | FQR | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||||
Myelodysplastic neoplasm with low blasts | Disease | FQR | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Myelodysplastic neoplasm, hypoplastic | Disease | FQR | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Myelodysplastic neoplasm with increased blasts | Disease | PENDING | FQR | Myelodysplastic Syndrome (MDS) with Excess Blasts | Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | Complete | ||||||||
Childhood myelodysplastic neoplasm with low blasts | Disease | PENDING | FQR | Refractory Cytopenia of Childhood | Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | Complete | ||||||||
Childhood myelodysplastic neoplasm with increased blasts | Disease | PENDING | FQR | Refractory Cytopenia of Childhood | Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | Complete | ||||||||
Chronic myelomonocytic leukaemia | Disease | PENDING | FQR | Chronic Myelomonocytic Leukemia (CMML) | Linsheng Zhang, MD, PhD | Complete | ||||||||
Myelodysplastic/myeloproliferative neoplasm with neutrophilia | Disease | PENDING | FQR | Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative | Linsheng Zhang, MD, PhD | Complete | ||||||||
Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis | Disease | PENDING | FQR | Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) | Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine | Complete | Date page was created | |||||||
Myelodysplastic/myeloproliferative neoplasm, NOS | Disease | PENDING | FQR | Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable | Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia | Complete | ||||||||
Acute promyelocytic leukaemia with PML::RARA fusion | Disease | PENDING | Jennelle Hodge (JH)/ Malini Sathanoori (MS) | Acute Promyelocytic Leukemia (APL) with PML-RARA | Yiming Zhong, Ph.D., Megan Piazza, Ph.D., and Shashi Shetty, Ph.D. | Complete | 03/01/2021-MS (re-review) | |||||||
Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion | Disease | PENDING | JH_MS | Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1 | Christine Bryke, MD Beth Israel Deaconess Medical Center, Boston, MA |
Complete | 04/26/2021-MS (re-review) | |||||||
Acute myeloid leukaemia with CBFB::MYH11 fusion | Disease | PENDING | JH_MS | Acute Myeloid Leukemia (AML) with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 | Christine Bryke, MD Beth Israel Deaconess Medical Center, Boston, MA |
Complete | 03/01/2021-MS (re-review) | |||||||
Acute myeloid leukaemia with DEK::NUP214 fusion | Disease | PENDING | JH_MS | Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214 | Jennelle C. Hodge, PhD, FACMG | Complete | 02/24/2021-MS (re-review) | |||||||
Acute myeloid leukaemia with RBM15::MRTFA fusion | Disease | PENDING | JH_MS | Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1 | Jennelle C. Hodge, PhD, FACMG | Complete | ||||||||
Acute myeloid leukaemia with BCR::ABL1 fusion | Disease | PENDING | JH_MS | Acute Myeloid Leukemia (AML) with BCR-ABL1 | Kay Weng Choy MBBS, Monash Medical Centre | Complete | ||||||||
Acute myeloid leukaemia with KMT2A rearrangement | Disease | PENDING | JH_MS | Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3 | Megan Piazza, Ph.D., Yiming Zhong, Ph.D., Shashi Shetty, Ph.D. | Complete | 03/01/2021-MS (re-review) | |||||||
Acute myeloid leukaemia with MECOM rearrangement | Disease | PENDING | JH_MS | Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM | Gordana Raca MD PhD, University of Southern California, Los Angeles | Complete | Need permission for figure? Update WHO? | |||||||
Acute myeloid leukaemia with NUP98 rearrangement | Disease | Eric McGinnis, MD | 12/20/23 | JH_MS | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||
Acute myeloid leukaemia with NPM1 mutation | Disease | PENDING | JH_MS | Acute Myeloid Leukemia (AML) with Mutated NPM1 | Xinjie Xu, PhD, FACMG | Complete | Add WHO reference | |||||||
Acute myeloid leukaemia with CEBPA mutation | Disease | PENDING | JH_MS | Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA | Paul Defazio, MSc, Monash Health | Complete | ||||||||
Acute myeloid leukaemia, myelodysplasia-related | Disease | PENDING | JH_MS | Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes | Fei Yang, MD, FACMG Oregon Health & Science University |
Complete | ||||||||
Acute myeloid leukaemia with other defined genetic alterations | Disease | JH_MS | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Acute myeloid leukaemia with minimal differentiation | Disease | PENDING | JH_MS | Acute Myeloid Leukemia (AML) with Minimal Differentiation | Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles, Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine | Complete | ||||||||
Acute myeloid leukaemia without maturation | Disease | PENDING | JH_MS | Acute Myeloid Leukemia (AML) without Maturation | Jennelle C. Hodge, PhD, FACMG | Complete | ||||||||
Acute myeloid leukaemia with maturation | Disease | PENDING | JH_MS | Acute Myeloid Leukemia (AML) with Maturation | Jennelle C. Hodge, PhD, FACMG | Complete | ||||||||
Acute basophilic leukaemia | Disease | PENDING | JH_MS | Acute Basophilic Leukemia | Ashwini Yenamandra PhD FACMG | Complete | ||||||||
Acute myelomonocytic leukaemia | Disease | PENDING | JH_MS | Acute Myelomonocytic Leukemia | Fei Yang, MD, FACMG Oregon Health & Science University |
Complete | ||||||||
Acute monocytic leukaemia | Disease | PENDING | JH_MS | Acute Monoblastic and Monocytic Leukemia | Fei Yang, MD, FACMG Oregon Health & Science University |
Complete | ||||||||
Acute erythroid leukaemia | Disease | PENDING | JH_MS | Pure Erythroid Leukemia | Ashwini Yenamandra PhD FACMG | Complete | ||||||||
Acute megakaryoblastic leukaemia | Disease | PENDING | JH_MS | Acute Megakaryoblastic Leukemia (AMKL) | Fei Yang, MD, FACMG Oregon Health & Science University |
Complete | ||||||||
Myeloid sarcoma | Disease | PENDING | JH_MS | Myeloid Sarcoma | Yalda Naeini, MD, School of Medicine at University of California Los Angeles Fabiola Quintero-Rivera, MD, FACMG, School of Medicine at University of California Irvine | Complete | ||||||||
RESOLVE 4th edition AML-Related NON-WHO entities content | Acute Myeloid Leukemia (AML) with Mutated FLT3 + Acute Myeloid Leukemia (AML) with NUP214-ABL1 + Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6 | ISSUE- FIX
|
||||||||||||
Myeloid neoplasm post cytotoxic therapy | Disease | PENDING | JH_MS | Therapy-Related Myeloid Neoplasms | Shawn A. Silver, DO, Shashi Shetty, Ph.D. | Complete | Check reference format | |||||||
Myeloid neoplasms associated with germline predisposition | Disease | PENDING | JH_MS | Multiple pages including overview page (Myeloid Neoplasms with Germline Predisposition - Compendium of Cancer Genome Aberrations (ccga.io)) and 6 disease pages ( HAEM4:Acute Myeloid Leukaemia with Germline CEBPA Mutation, HAEM4:Myeloid Neoplasms with Germline DDX41 Mutation, HAEM4:Myeloid Neoplasms with Germline ETV6 Mutation, HAEM4:Myeloid Neoplasms with Germline GATA2 Mutation, HAEM4:Myeloid Neoplasms with Germline RUNX1 Mutation, HAEM4:Myeloid Neoplasms with Germline ANKRD26 Mutation) | See links from instructions on the 5th edition page | Complete | Most were re-reviewed by MS on 03/02/2021 | For page Acute Myeloid Leukaemia with Germline CEBPA Mutation - Note by MS of "Review completed, awaiting some clarification from JH - 07/04/2022" | ||||||
Myeloid proliferations associated with Down syndrome | Disease | PENDING | JH_MS | MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome | Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO | Complete (all three pages) | ||||||||
Myeloid/lymphoid neoplasm with PDGFRA rearrangement | Disease | PENDING | FQR | Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement | Jay Alden, DO | Complete | ||||||||
Myeloid/lymphoid neoplasm with PDGFRB rearrangement | Disease | PENDING | FQR | Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement | Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD | Complete | ||||||||
Myeloid/lymphoid neoplasm with FGFR1 rearrangement | Disease | PENDING | FQR | Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement | Yanna Ding, MD PhD | Complete | ||||||||
Myeloid/lymphoid neoplasm with JAK2 rearrangement | Disease | ISSUE- FIX
|
FQR | Myeloid/Lymphoid Neoplasms with PCM1-JAK2 + consider a non-WHO page Myeloid/Lymphoid Neoplasms with ETV6-JAK2 (Myeloid/Lymphoid Neoplasms with ETV6-JAK2 - Compendium of Cancer Genome Aberrations (ccga.io)) + another non-WHO page Myeloid/Lymphoid Neoplasms with BCR-JAK2 (Myeloid/Lymphoid Neoplasms with BCR-JAK2 - Compendium of Cancer Genome Aberrations (ccga.io) ) - both non-WHO pages are authored by trainee Lauren Crowson-Hindman and Daynna Wolff | Jessica Snider, M.D. and Daynna J. Wolff, PhD + non-WHO pages by trainee Lauren Crowson-Hindman and Daynna Wolff | Complete | ||||||||
Myeloid/lymphoid neoplasm with FLT3 rearrangement | Disease | FQR | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion | Disease | FQR | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes | Disease | FQR | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Mixed-phenotype acute leukaemia with BCR::ABL1 fusion | Disease | PENDING | JH_MS | Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 | Tracy Tucker, PhD, FCCMG | Complete | ||||||||
Mixed-phenotype acute leukaemia with KMT2A rearrangement | Disease | PENDING | JH_MS | Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged | Tracy Tucker, PhD, FCCMG | Complete | ||||||||
Acute leukaemia of ambiguous lineage with other defined genetic alterations | Disease | JH_MS | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Mixed-phenotype acute leukaemia, B/myeloid | Disease | PENDING | JH_MS | Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified | Priyatharsini Nirmalanantham, MD and Shashi Shetty, PhD | Complete | ||||||||
Mixed-phenotype acute leukaemia, T/myeloid | Disease | PENDING | JH_MS | Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified | Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine | Complete | ||||||||
Mixed-phenotype acute leukaemia, rare types | Disease | PENDING | JH_MS | Mixed-Phenotype Acute Leukemia, Not Otherwise Specified (NOS), Rare Types | Elicia Goodale, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | PENDING | ||||||||
Acute leukaemia of ambiguous lineage, NOS | Disease | JH_MS | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Acute undifferentiated leukaemia | Disease | PENDING | JH_MS | Acute Undifferentiated Leukemia | Amelia Nakanishi, MD and Shashi Shetty, PhD | Complete | Check reference format | |||||||
CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm | Disease | Greg Corboy (GC) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Blastic plasmacytoid dendritic cell neoplasm | Disease | PENDING | GC | Blastic Plasmacytoid Dendritic Cell Neoplasm | Hao Liu, MD and Daynna J. Wolff, PhD | Complete | Previously within myeloid section under JH/MS editors | |||||||
Langerhans cell histiocytosis | Disease | PENDING | GC | Langerhans Cell Histiocytosis | Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | Complete | 5/19/2022 |
Date completed by author: 04/28/2022 | ||||||
Langerhans cell sarcoma | Disease | PENDING | GC | Langerhans Cell Sarcoma | Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | Complete | 5/19/2022 |
Date completed by author: 04/28/2022 | ||||||
Indeterminate dendritic cell tumour | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Interdigitating dendritic cell sarcoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Juvenile xanthogranuloma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Erdheim-Chester disease | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Rosai-Dorfman Disease | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
ALK-positive histiocytosis | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Histiocytic sarcoma | Disease | PENDING | GC | Histiocytic Sarcoma | Marie-France Gagnon, MD, Mayo Clinic, Xinjie Xu, PhD FACMG, Mayo Clinic | Complete | 10/01/2021 | Date completed by author: 10/01/2021 | ||||||
CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reactive B-cell rich lymphoid proliferations that can mimic lymphoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
IgG4-related disease | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Unicentric Castleman disease | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Idiopathic multicentric Castleman disease | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
KSHV/HHV8-associated multicentric Castleman disease | Disease | PENDING | GC | Multicentric Castleman Disease | Sudha Arumugam, MD | Complete | 01/24/2022 | Date completed by author: 01/24/2022 | ||||||
B-lymphoblastic leukaemia/lymphoma | Disease | PENDING | Holli Drendel (HD) | B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified | Holli Drendel | PENDING | ||||||||
B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy | Disease | PENDING | HD | B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy | Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG | PENDING | ||||||||
B-lymphoblastic leukaemia/lymphoma with hypodiploidy | Disease | PENDING | HD | B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy | Ashwini Yenamandra PhD FACMG Lisa Smith PhD FACMG Yassmine Akkari PhD FACMG | Complete | ||||||||
B-lymphoblastic leukaemia/lymphoma with iAMP21 | Disease | Holli Drendel authoring - Complete? Looks like needs more editing of tables | HD | B-Lymphoblastic Leukemia/Lymphoma with iAMP21 [but was completed as a 5th edition page by Holli] | Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte | ?Complete | ||||||||
B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion | Disease | PENDING | HD | B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 | Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG | PENDING | ||||||||
B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features | Disease | PENDING | HD | B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Mark G. Evans, MD, University of California, Irvine Fabiola Quintero-Rivera, MD, University of California, Irvine | Complete | ||||||||
B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement | Disease | PENDING | HD | B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged | Yassmine Akkari Nicolas Millan | PENDING | ||||||||
B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion | Disease | PENDING | HD | B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion | Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG Cancer Category/Type B-Lymphoblastic Leukemia/Lymphoma | PENDING | ||||||||
B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features | Disease | HD | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion | Disease | PENDING | HD | B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1 | Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO | PENDING | ||||||||
B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion | Disease | PENDING | HD | B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3 | Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO | PENDING | ||||||||
B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion | Disease | HD | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations | Disease | HD | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
B-lymphoblastic leukaemia/lymphoma, NOS | Disease | HD | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
RESOLVE 4th edition ALL-Related NON-WHO entities content | B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 + B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6 + B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements + B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions + B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19) + B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11) | ISSUE- FIX
|
ISSUE - FIX | |||||||||||
Monoclonal B-cell lymphocytosis | Disease | PENDING | Shivani Golem (SG) | Monoclonal B-cell Lymphocytosis | Tsigab Bahta Hagos (trainee) / Shashirekha Shetty | PENDING | Assigned 12/19/2022 with completion date of 1/19/2023 | |||||||
Chronic lymphocytic leukaemia/small lymphocytic lymphoma | Disease | Jaime Nagy, PhD, University of Iowa
Renee Eigsti, MD, Pathology Services of Kalamazoo Honey Reddi, PhD, Belay Diagnostics |
Complete (Shivani, please confirm) | SG | Already converted to 5th edition | Jamie Nagy, PhD, University of Iowa Honey Reddi, PhD | ||||||||
Hairy cell leukaemia | Disease | PENDING | SG | Hairy Cell Leukemia | Snehal Patel, MD, PhD | Complete | ||||||||
Splenic marginal zone lymphoma | Disease | PENDING | SG | Splenic Marginal Zone Lymphoma | Snehal Patel, MD, PhD | Complete | ||||||||
Splenic diffuse red pulp small B-cell lymphoma | Disease | PENDING | SG | Splenic Diffuse Red Pulp Small B-cell Lymphoma | Snehal Patel, MD, PhD | Complete | ||||||||
Splenic B-cell lymphoma/leukaemia with prominent nucleoli | Disease | PENDING | SG | Hairy Cell Leukemia Variant | Snehal Patel, MD, PhD | Complete | ||||||||
Lymphoplasmacytic lymphoma | Disease | PENDING | SG | (1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia | (1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI) | Complete | 4/12/2023 by FQR | |||||||
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue | Disease | PENDING | SG | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) | Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG*
Department of Pathology and Laboratory Medicine and *Pediatrics, School of Medicine, University of California Irvine (UCI) |
Complete | 4/12/23 by FQR | |||||||
Primary cutaneous marginal zone lymphoma | Disease | SG | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Nodal marginal zone lymphoma | Disease | PENDING | SG | Nodal Marginal Zone Lymphoma | Andrew Ly, DO and Shivani Golem, PhD, FACMG | Complete | 5/28/2021 | |||||||
Paediatric nodal marginal zone lymphoma | Disease | PENDING | SG | Paediatric Nodal Marginal Zone Lymphoma | * Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD | Complete | 11/11/2020 | |||||||
In situ follicular B-cell neoplasm | Disease | Rachel D. Burnside, PhD, MBA, FACMGG | 7/28/2023 | Pending | SG | In Situ Follicular Neoplasia | Rachel D. Burnside, PhD, MBA, FACMGG | Pending | ||||||
Follicular lymphoma | Disease | Rachel D. Burnside, PhD, MBA, FACMGG | 7/28/2023 | Pending | SG | Author also needs to correlate with 4th edition disease "Testicular Follicular Lymphoma", which is no longer a separate entity | (1) Follicular Lymphoma + (2) Testicular Follicular Lymphoma | (1 and 2) Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital Rachel D. Burnside, PhD, MBA, FACMG, University of Florida | Pending | |||||
Paediatric-type follicular lymphoma | Disease | PENDING | SG | Paediatric-Type Follicular Lymphoma | *Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG | Complete | 8/16/2020 | |||||||
Duodenal-type follicular lymphoma | Disease | Rachel D. Burnside, PhD, MBA, FACMGG | 7/28/2023 | Pending | SG | Duodenal-Type Follicular Lymphoma | No prior content | |||||||
Primary cutaneous follicle centre lymphoma | Disease | PENDING | SG | Primary Cutaneous Follicle Centre Lymphoma | Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG | Complete | 09/10/2022 | |||||||
In situ mantle cell neoplasm | Disease | PENDING | SG | In Situ Mantle Cell Neoplasia | Rina Kansal, MD; Versiti Blood Center of Wisconsin | Complete | 7/26/2022 | |||||||
Mantle cell lymphoma | Disease | PENDING | SG | Mantle Cell Lymphoma | * Mahsa Khanlari, MD * Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas | Pending | Target completion date 8/15/20 | |||||||
Leukaemic non-nodal mantle cell lymphoma | Disease | SG | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Transformations of indolent B-cell lymphomas | Disease | SG | Include content on chronic myelomonocytic leukemia in transformation and refractory anaemia with excess blasts in transformation | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||||
Diffuse large B-cell lymphoma, NOS | Disease | PENDING | GC | Diffuse Large B-cell Lymphoma, Not Otherwise Specified | Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center | Pending | Requested to update 14022022 | |||||||
T-cell/histiocyte-rich large B-cell lymphoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements | Disease | PENDING | GC | High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | Kate Berry, MBBS, BBus (Hons), Pathology Queensland | Complete | 24/02/2022 | |||||||
ALK-positive large B-cell lymphoma | Disease | PENDING | GC | ALK-Positive Large B-cell Lymphoma | Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) | Pending | Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23 | |||||||
Large B-cell lymphoma with IRF4 rearrangement | Disease | PENDING | GC | Large B-cell Lymphoma with IRF4 Rearrangement | Afia Hasnain, MBBS, PhD | Complete | 5/26/2021 | |||||||
High grade B-cell lymphoma with 11q aberrations | Disease | PENDING | GC | Burkitt-Like Lymphoma with 11q Aberration | Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | Comlete | 27/01/2022 | |||||||
Lymphomatoid granulomatosis | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
EBV-positive diffuse large B-cell lymphoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Diffuse large B-cell lymphoma associated with chronic inflammation | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Fibrin-associated large B-cell lymphoma | Disease | PENDING | GC | Note: previously a subset DLBCL assoc with chronic inflam | Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||
Fluid overload-associated large B-cell lymphoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Plasmablastic lymphoma | Disease | PENDING | GC | Plasmablastic Lymphoma | Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | Complete | 28/03/2022 | |||||||
Primary large B-cell lymphoma of immune-privileged sites | Disease | PENDING | GC | (1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS | (1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital | (1) Pending + (2) Complete | (1) Not ready + (2) 03/28/22 | For "Diffuse Large B-cell Lymphoma, Not Otherwise Specified" page from Ash, Greg requested to update 14022022 | ||||||
Primary cutaneous diffuse large B-cell lymphoma, leg type | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Intravascular large B-cell lymphoma | Disease | PENDING | GC | Intravascular Large B-cell Lymphoma | Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy | Complete | 9/1/22 | Emailed 28/3/2022 for progress update | ||||||
Primary mediastinal large B-cell lymphoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Mediastinal grey zone lymphoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
High-grade B-cell lymphoma, NOS | Disease | PENDING | GC | High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS) | Aiko Otsubo, PhD, Indiana University, Holli Drendel | Complete | 16/11/2021 | |||||||
Burkitt lymphoma | Disease | PENDING | GC | Burkitt Lymphoma | Becky Leung, MBBS (Hons), BSc, Pathology Queensland | Complete | 28/06/2021 | |||||||
Primary effusion lymphoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
KSHV/HHV8-positive diffuse large B-cell lymphoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
KSHV/HHV8-positive germinotropic lymphoproliferative disorder | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Hyperplasias arising in immune deficiency/dysregulation | Disease | FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others") | GC | |||||||||||
Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation | Disease | FIX ISSUE! (on 5th edition page instructions say "This page was converted to the new template on 2023-12-07. The original page can be found at HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders.
Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others)" |
GC | Polymorphic Post-Transplant Lymphoproliferative Disorders | Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI) | Completed | 26/4/2022 | |||||||
EBV-positive mucocutaneous ulcer | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Lymphomas arising in immune deficiency / dysregulation | Disease | FIX ISSUE! (on 5th edition page instructions say "encompassing monomorphic PTLD, classic HL PTLD, lymphomas assoc with HIV infection, among others" | GC | |||||||||||
Inborn error of immunity-associated lymphoid proliferations and lymphomas | Disease | FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]") | GC | |||||||||||
Classic Hodgkin lymphoma | Disease | PENDING | Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma | GC | (1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma | (1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez | Pending + Completed (03/21/22) | Not completed for checking (1, 3 and 4) + 03/21/22 (2) | ||||||
Nodular lymphocyte predominant Hodgkin lymphoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Cold agglutinin disease | Disease | SG | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
IgM monoclonal gammopathy of undetermined significance | Disease | SG | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Non-IgM monoclonal gammopathy of undetermined significance | Disease | SG | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Monoclonal gammopathy of renal significance | Disease | SG | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Immunoglobulin-related (AL) amyloidosis | Disease | PENDING | SG | Primary Amyloidosis | Heather E. Williams, PhD, MS, PgD, ErCLG | ?PENDING |
||||||||
Monoclonal immunoglobulin deposition disease | Disease | PENDING | SG | Light Chain and Heavy Chain Deposition Disease | Chen Yang, MD, PhD, University of Michigan | Complete | 10/15/2022 | |||||||
Mu heavy chain disease | Disease | SG | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Gamma heavy chain disease | Disease | PENDING | SG | Gamma Heavy Chain Disease | Manisha Brahmbhatt-Sutariya Asst. Professor, Dept. of Pathology and Human Anatomy Technical Supervisor, Clinical Genetics Laboratory Loma Linda University, Medical Center, CA | Complete | 5/26/2021 | |||||||
Alpha heavy chain disease | Disease | SG | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Plasmacytoma | Disease | PENDING | author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga) | SG | NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||
Plasma cell myeloma / multiple myeloma | Disease | PENDING | Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page | SG | (1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants | (1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG | Pending | |||||||
Plasma cell neoplasms with associated paraneoplastic syndrome | Disease | PENDING | Note: author needs to include POEMS, TEMPI, and look for AESOP content | SG | (1) POEMS Syndrome + (2) TEMPI Syndrome | (1 and 2) Sohini Anand, MBBS Tharanga Niroshini Senaratne, PhD | ?PENDING | |||||||
CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Kikuchi-Fujimoto disease | Disease | Sumi Kitahara (SK) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Autoimmune lymphoproliferative syndrome | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Indolent T-lymphoblastic proliferation | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
T-lymphoblastic leukaemia / lymphoma, NOS | Disease | HD | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Early T-precursor lymphoblastic leukaemia / lymphoma | Disease | PENDING | HD | Early T-Cell Precursor Lymphoblastic Leukemia | Fei Yang, MD, FACMG, Kaiser Permanente Northwest | Pending | ||||||||
T-prolymphocytic leukaemia | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
T-large granular lymphocytic leukaemia | Disease | PENDING | SK | T-cell Large Granular Lymphocytic Leukemia | Michelle Don, MD, MS | Pending | ||||||||
NK-large granular lymphocytic leukaemia | Disease | PENDING | SK | Chronic Lymphoproliferative Disorder of NK Cells | Michelle Don, MD | Pending | ||||||||
Adult T-cell leukaemia/lymphoma | Disease | PENDING | SK | Adult T-cell Leukemia/Lymphoma | Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center | ?Pending | ||||||||
Sezary syndrome | Disease | PENDING | SK | Sézary Syndrome | Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina | Pending | ||||||||
Aggressive NK-cell leukaemia | Disease | PENDING | SK | Aggressive NK-cell Leukemia | Shanelle De Lancy, MD, Shashirekha Shetty, PhD | ?Pending | ||||||||
Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Mycosis fungoides | Disease | PENDING | SK | Mycosis Fungoides | Jane Scribner, MD and Daynna J. Wolff, PhD | Pending | ||||||||
Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma | Disease | PENDING | SK | Primary Cutaneous Anaplastic Large Cell Lymphoma | Theresa Spivey, MD, Shashirekha Shetty, PhD | Pending | ||||||||
Subcutaneous panniculitis-like T-cell lymphoma | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Primary cutaneous gamma/delta T-cell lymphoma | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Primary cutaneous peripheral T-cell lymphoma, NOS | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Indolent T-cell lymphoma of the gastrointestinal tract | Disease | PENDING | SK | Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract | Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | Pending | ||||||||
Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Enteropathy-associated T-cell lymphoma | Disease | PENDING | SK | Enteropathy-Associated T-cell Lymphoma | *Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD | Complete | 1/21/2021 | |||||||
Monomorphic epitheliotropic intestinal T-cell lymphoma | Disease | PENDING | SK | Monomorphic Epitheliotropic Intestinal T-cell Lymphoma | Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | Pending | ||||||||
Intestinal T-cell lymphoma, NOS | Disease | PENDING | SK | Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS) | Derick Okwan MD, PhD (Stanford Medicine, CA) Sumire Kitahara MD (Cedars-Sinai, CA) | Complete | 9/26/2022 | |||||||
Hepatosplenic T-cell lymphoma | Disease | PENDING | SK | Hepatosplenic T-cell Lymphoma | Michelle Don, MD, MS | Complete | 1/21/2021 | |||||||
ALK-positive anaplastic large cell lymphoma | Disease | PENDING | SK | Anaplastic Large Cell Lymphoma, ALK-Positive | Miguel Gonzalez Mancera, MD
Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA |
Complete | 09/23/2022 | |||||||
ALK-negative anaplastic large cell lymphoma | Disease | PENDING | SK | Anaplastic Large Cell Lymphoma, ALK-Negative | Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA | Complete | 09/23/2022 | |||||||
Breast implant-associated anaplastic large cell lymphoma | Disease | PENDING | SK | Breast Implant-Associated Anaplastic Large Cell Lymphoma | Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center | Pending | ||||||||
Nodal TFH cell lymphoma, angioimmunoblastic-type | Disease | Issue - Rachel Burnside was working on this. Note says: "has prior content and name will change in 5th edition - Rachel working on this outside of production site to be replaced later by Nodal TFH Cell Lymphoma, Angioimmunoblastic-Type)". Where is her content as previous author names on 5th edition page | 7/28/2023 | Pending | SK | Angioimmunoblastic T-cell Lymphoma | Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG | Pending | ||||||
Nodal TFH cell lymphoma, follicular-type | Disease | Rachel Burnside | 7/28/2023 | Pending | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||
Nodal TFH cell lymphoma, NOS | Disease | PENDING | SK | Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype | Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD | Pending | ||||||||
Peripheral T-cell lymphoma, NOS | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
EBV-positive nodal T- and NK-cell lymphoma | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Extranodal NK/T-cell lymphoma | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Severe mosquito bite allergy | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Hydroa vacciniforme lymphoproliferative disorder | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Systemic chronic active EBV disease | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Systemic EBV-positive T-cell lymphoma of childhood | Disease | PENDING | SK | Systemic EBV-Positive T-cell Lymphoma of Childhood | Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA | Complete | 11/21/2021 | |||||||
CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Follicular dendritic cell sarcoma | Disease | PENDING | GC | Follicular Dendritic Cell Sarcoma | Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG | ?Pending | ||||||||
EBV-positive inflammatory follicular dendritic cell sarcoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Fibroblastic reticular cell tumour | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Intranodal palisaded myofibroblastoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Littoral cell angioma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Splenic hamartoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Sclerosing angiomatoid nodular transformation (SANT) of spleen | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
CHAPTER 7 (GENETIC TUMOUR SYNDROMES) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fanconi anaemia | Disease | NA | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Bloom syndrome | Disease | NA | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Ataxia-telangiectasia syndrome | Disease | NA | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
RASopathies | Disease | NA | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) |